Overview of Skin Cancers for General Practitioners

Tarek Haykal

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

Imaging Considerations for the Dermatologist

Masterclasses in Dermatology

C. Bakewell

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

2024 ASCO® Annual Meeting Insights Hub

C. Blank

Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

Mees Egeler

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi

How to Manage: Melanonychia

EADV 2022 Conference Coverage

M. Starace

Promoting Skin Self-Exam for the Secondary Prevention of Melanoma

David Polsky

2024 Updates on Neoadjuvant Therapy for Resectable Melanoma

Winship Melanoma and Cutaneous Oncology Symposium

S. Patel

ESMO 2024 Insights: Survival Impact of Adjuvant Treatment in Stage I…

2024 ESMO Annual Meeting Insights Hub

H. Helgadottir

Increasing Melanoma Incidence with Unchanged Mortality, 1999 - 2019

Jesper Bo Nielsen

Top Risk Factors for Cancer by Sex and What to Do About It

MedCram

R. Seheult

Year in Review: Surgical Treatment of Acral Melanoma

2023 Year in Review

M. Leventer

Medical Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunothera…

2024 ASCO® Annual Meeting Insights Hub

H. Kluger